C25H31N9O2
Neat
489.58
golidocitinib; AZD-4205; AZD4205; UNII-3BY9Z3M34G; 3BY9Z3M34G; (2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide; GOLIDOCITINIB [INN]; (2R)-N-(3-(2-((3-methoxy-1-methylpyrazol-4-yl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide; (ALPHAR)-N-(3-(2-((3-METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO)-4-PYRIMIDINYL)-1H-INDOL-7-YL)-ALPHA, 4-DIMETHYL-1-PIPERAZINEACETAMIDE; (alphaR)-N-[3-[2-[(3-Methoxy-1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-alpha, 4-dimethyl-1-piperazineacetamide; AZD 4205; RefChem:144119; JAK1 Inhibitor AZD4205; (.ALPHA.R)-N-(3-(2-((3-METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO)-4-PYRIMIDINYL)-1H-INDOL-7-YL)-.ALPHA., 4-DIMETHYL-1-PIPERAZINEACETAMIDE; 2091134-68-6; JAK1-IN-3; (R)-N-(3-(2-((3-Methoxy-1-methyl-1h-pyrazol-4-yl)amino)pyrimidin-4-yl)-1h-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-{2-[(3-Methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha, 4-dimethyl-, (alphaR)-; 1-Piperazineacetamide, N-[3-[2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-alpha, 4-dimethyl- and (alphaR)-
(2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1